论文部分内容阅读
目的探讨血小板减少性疾病患者血清血小板生成素(Tpo)与疾病性质的关系和临床意义。方法采用夹心酶联免疫法测定恶性血液病(急性淋巴细胞性白血病、急性非淋巴细胞性白血病、骨髓增生异常综合征和多发性骨髓瘤)患者、自身免疫性疾病患者、再生障碍性贫血患者、脾功能亢进症患者、病毒感染者及正常对照者的血清Tpo水平;恶性血液病患者治疗缓解后复测血清Tpo水平,观察其变化。结果治疗前恶性血液病患者与对照者的血清Tpo值间差别有显著性意义(P<0.05),恶性血液病患者治疗缓解后血清Tpo水平与对照者间差别无显著性意义(P>0.05);其他疾病相关的继发性血小板减少患者血清Tpo值与对照者间差别亦无显著性意义(P>0.05)。结论恶性血液病患者血清Tpo水平升高,治疗缓解后Tpo水平恢复正常;其他疾病相关的继发性血小板减少患者Tpo水平无明显变化。
Objective To investigate the relationship between serum thrombopoietin (Tpo) and the disease in patients with thrombocytopenic diseases and its clinical significance. Methods Sandwich enzyme-linked immunosorbent assay (ELISA) was used to detect patients with hematologic malignancies (acute lymphoblastic leukemia, acute non-lymphocytic leukemia, myelodysplastic syndrome and multiple myeloma), patients with autoimmune diseases, patients with aplastic anemia, Serum Tpo levels in patients with hypersplenism, virus infection and normal controls; serum Tpo levels were measured in patients with hematologic malignancies after remission, and the changes were observed. Results There was significant difference between the two groups (P <0.05), but there was no significant difference between the two groups (P> 0.05) There was no significant difference between Tpo values of other disease-related patients with secondary thrombocytopenia and those of controls (P> 0.05). Conclusions Serum Tpo level is elevated in patients with hematologic malignancies, and the level of Tpo returns to normal after remission. There is no significant change in Tpo levels in patients with other diseases related to secondary thrombocytopenia.